Clinical Trial Update: Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) [Phase 1]

View source ↗

Summary

A Phase 1 (Phase IB) trial evaluating Radium-223 dichloride in combination with niraparib for castration-resistant, metastatic prostate cancer has completed its…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)
• Zejula (Niraparib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Prostate Carcinoma Metastatic to the Bone, Stage IV Prostate Adenocarcinoma | Phase 1 | Status: COMPLETED